Beryl Drugs
Healthcare
524606 BSE
₹23.24
Close ·
- P/E
- 19.21
Close 4 Nov 2026 ₹23.24 +0.14 +0.61% 1Y
Start ₹23.10
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 7.25%
- Debt to Equity
- 0.25
- EPS (TTM)
- ₹1.21
- Book Value
- ₹19.45
- Market Cap
- —
- P/E (TTM)
- 19.21
- P/B
- 1.19
- ROE
- 4.34%
- Dividend Yield
- 0.00%
- EBITDA
- ₹2.40 Cr
- 52W High
- ₹27.90
- 52W Low
- ₹15.92
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
56 Good
Data confidence 100/100
Category scores
- Quality
- 59
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 60
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 44
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 42
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 69
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 51
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Debtor days have improved from 79.4 to 40.6 days.
- Company's working capital requirements have reduced from 55.4 days to 40.4 days
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 6.04% over past five years.
- Promoter holding is low: 27.8%
- Company has a low return on equity of 6.39% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 6 | 3 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bearish | 8 | 0 | 2 |
Oscillators
Bearish
Bearish
2
Neutral
6
Bullish
1
Overall
Strong Bearish
Bearish
10
Neutral
6
Bullish
3
Moving Averages
Strong Bearish
Bearish
8
Neutral
0
Bullish
2
Key readings
- RSI (14)
- 45.04
- Neutral
- MACD (12,26,9)
- 0.01
- Bearish
- SMA (50)
- 24.24
- Bearish
- SMA (200)
- 22.46
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +3.77% |
|---|---|
| 5Y | +6.04% |
| 3Y | −11.17% |
| 1Y | −11.06% |
| TTM | +4.55% |
Net profit
| 10Y | +9.47% |
|---|---|
| 5Y | +11.84% |
| 3Y | −18.29% |
| 1Y | −26.32% |
| TTM | +169.57% |
Operating cash flow
| 10Y | Turned positive |
|---|---|
| 5Y | +60.75% |
| 3Y | +13.75% |
| 1Y | +10.94% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +6.46 pp |
|---|---|
| 5Y | −0.02 pp |
| 3Y | +2.86 pp |
| 1Y | +4.45 pp |
| TTM | +1.00 pp |
Revenue by year
| Mar 2017 | ₹10.90 Cr |
|---|---|
| Mar 2018 | ₹15.08 Cr |
| Mar 2019 | ₹12.81 Cr |
| Mar 2020 | ₹12.78 Cr |
| Mar 2021 | ₹14.03 Cr |
| Mar 2022 | ₹14.48 Cr |
| Mar 2023 | ₹26.84 Cr |
| Mar 2024 | ₹26.73 Cr |
| Mar 2025 | ₹21.15 Cr |
| Mar 2026 | ₹18.81 Cr |
Net profit by year
| Mar 2017 | −₹0.45 Cr |
|---|---|
| Mar 2018 | ₹0.99 Cr |
| Mar 2019 | ₹0.59 Cr |
| Mar 2020 | ₹0.05 Cr |
| Mar 2021 | ₹0.24 Cr |
| Mar 2022 | −₹0.66 Cr |
| Mar 2023 | ₹0.77 Cr |
| Mar 2024 | ₹0.77 Cr |
| Mar 2025 | ₹0.57 Cr |
| Mar 2026 | ₹0.42 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.18 | 8.09 | 7.66 | 3.21 | 6.29 | 5.64 | 5.4 | 5.22 | 4.83 | 5.16 | 3.85 | 5.47 | 7.57 |
| Expenses | 7.05 | 7.37 | 6.87 | 3.19 | 5.3 | 5.08 | 4.81 | 4.72 | 4.28 | 4.43 | 4.05 | 4.13 | 6.92 |
| Operating Profit | 1.13 | 0.72 | 0.79 | 0.02 | 0.99 | 0.56 | 0.59 | 0.5 | 0.55 | 0.73 | −0.2 | 1.34 | 0.65 |
| OPM % | 13.81% | 8.9% | 10.31% | 0.62% | 15.74% | 9.93% | 10.93% | 9.58% | 11.39% | 14.15% | −5.19% | 24.5% | 8.59% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.12 | 0.1 | 0.11 | 0.13 | 0.21 | 0.12 | 0.12 | 0.08 | 0.1 | 0.08 | 0.09 | 0.07 | 0.06 |
| Depreciation | 0.28 | 0.29 | 0.31 | 0.32 | 0.28 | 0.33 | 0.31 | 0.32 | 0.38 | 0.39 | 0.32 | 0.4 | 0.32 |
| PBT | 0.73 | 0.33 | 0.37 | −0.43 | 0.5 | 0.11 | 0.16 | 0.1 | 0.07 | 0.26 | −0.61 | 0.87 | 0.27 |
| Tax % | 27.4% | 18.18% | 16.22% | −16.28% | 26% | 90.91% | 62.5% | −50% | 71.43% | 96.15% | −72.13% | 34.48% | 18.52% |
| Net Profit | 0.53 | 0.27 | 0.31 | −0.35 | 0.37 | 0.01 | 0.05 | 0.15 | 0.02 | 0.01 | −0.17 | 0.56 | 0.22 |
| EPS (₹) | 1.05 | 0.53 | 0.61 | −0.69 | 0.73 | 0.02 | 0.1 | 0.3 | 0.04 | 0.02 | −0.34 | 1.1 | 0.43 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.23 | 12.99 | 10.9 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 18.81 | 22.05 |
| Expenses | 12.5 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.45 | 19.91 | 16.87 | 19.53 |
| Operating Profit | 0.73 | 0.5 | −0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2 | 2.28 | 1.24 | 1.94 | 2.52 |
| OPM % | 5.52% | 3.85% | −0.55% | 6.9% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 10.31% | 11.43% |
| Other Income | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.4 | 1.41 | 0.49 | 0 |
| Interest | 0.26 | 0.21 | 0.2 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.47 | 0.54 | 0.35 | 0.3 |
| Depreciation | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.2 | 1.26 | 1.49 | 1.43 |
| PBT | 0.13 | 0.25 | −0.37 | 1.27 | 0.8 | 0.16 | 0.35 | −0.95 | 0.99 | 1.01 | 0.85 | 0.59 | 0.79 |
| Tax % | 38.46% | 32% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | −30.53% | 22.22% | 23.76% | 34.12% | 27.12% | — |
| Net Profit | 0.08 | 0.17 | −0.45 | 0.99 | 0.59 | 0.05 | 0.24 | −0.66 | 0.77 | 0.77 | 0.57 | 0.42 | 0.62 |
| EPS (₹) | 0.16 | 0.34 | −0.89 | 1.95 | 1.16 | 0.1 | 0.47 | −1.3 | 1.52 | 1.52 | 1.12 | 0.83 | 1.21 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.4 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.2 | 2.97 | 3.83 | 4.39 | 4.79 |
| Borrowings | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.12 | 2.44 |
| Other Liabilities | 2.71 | 1.8 | 2.85 | 2.69 | 3.8 | 4.07 | 5.6 | 5.25 | 4.92 | 3.48 | 2.38 | 2.65 |
| Total Liabilities | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.98 | 14.97 |
| Fixed Assets | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.6 | 7.52 | 6.04 | 6.03 | 6.17 | 6.24 | 7.04 |
| CWIP | 0.24 | 0 | 0 | 0.08 | 6.24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0 | 0 | 0 |
| Other Assets | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.74 | 7.93 |
| Total Assets | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.98 | 14.97 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.7 | −0.13 | 0.37 | −0.1 | 3.35 | 0.18 | 0.34 | −0.29 | 2.48 | 0.82 | 3.29 | 3.65 |
| Investing | 0.02 | 0.17 | 0.32 | −0.03 | −5.01 | −1.55 | 0.26 | 0.54 | −1.3 | −1.08 | −1.05 | −2.16 |
| Financing | −0.09 | −0.23 | −0.19 | −0.36 | 1.62 | 1.67 | −0.54 | −0.43 | −1.17 | 0.1 | −1.56 | −2.03 |
| Net Cash Flow | 0.63 | −0.19 | 0.5 | −0.49 | −0.04 | 0.3 | 0.06 | −0.18 | 0.01 | −0.16 | 0.69 | −0.54 |
| Free Cash Flow | 0.47 | −0.33 | 0.19 | −0.01 | −2.87 | −1.7 | 0.1 | 0.1 | 1.73 | −0.51 | 1.1 | −0.17 |
| CFO/OP | 125 | 6 | −833 | 1 | 350 | 36 | 25 | −43 | 127 | 45 | 280 | 196 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 101 | 102 | 117 | 98.02 | 98.53 | 118 | 112 | 93.83 | 104 | 94.23 | 40.56 |
| Inventory Days | 64.34 | 65.28 | 151 | 53.1 | 39.74 | 487 | 1,135 | — | 246 | — | — | — |
| Days Payable | 69.91 | 34.34 | 65.24 | 57.03 | 93.6 | 755 | 1,110 | — | 758 | — | — | — |
| Cash Conversion Cycle | 96.5 | 132 | 189 | 113 | 44.16 | −170 | 143 | 112 | −419 | 104 | 94.23 | 40.56 |
| Working Capital Days | 38.35 | 58.44 | 67.31 | 71.89 | −6.55 | 13.99 | 38.76 | 47.14 | 46.51 | 57.9 | 68 | 40.36 |
| ROCE % | 5.2% | 5.56% | −2.26% | 11.94% | 9.94% | 4.06% | 2.86% | −3.82% | 11.6% | 11.05% | 10.07% | 7.25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Beryl Drugs insights
59 extracted metrics across FY10–FY27.
Documents
- General announcements 7 Oct 2026
Frequently Asked Questions about Beryl Drugs
What does Beryl Drugs Ltd do?
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing
Where is Beryl Drugs Ltd (BERLDRG) listed?
Beryl Drugs Ltd trades under code 524606 on the BSE.
Which sector does Beryl Drugs Ltd belong to?
Beryl Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd trades at a PE ratio of 19.21 as of 4 Nov 2026, on earnings per share of ₹1.21, against a book value of ₹19.45 per share.
What is the 52-week high and low of Beryl Drugs Ltd?
Over the last 52 weeks Beryl Drugs Ltd has traded between ₹15.92 and ₹27.9 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Beryl Drugs Ltd?
Beryl Drugs Ltd reported a return on equity of 4.34%. Its debt-to-equity ratio is 0.25.
Company Information
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524606.md for Beryl Drugs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.